Bio-Path Holdings: Funding, Investors & Team (Oct 2026)
Bio-Path is a biotechnology company developing DNAbilize, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous infusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and prexigebersen-A, a drug product modification of prexigebersen, is under consideration by the FDA to commence Phase 1 studies in solid tumors.
Bio-Path Holdings has raised $11.2M across 4 funding rounds on record, the most recent an undisclosed round of $4.0M announced in Oct 2024.
That round is below the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Bio-Path Holdings Company Profile and Key Stats
Latest funding round on record: Oct 2024.
Bio-Path Holdings Funding Rounds
Bio-Path Holdings raised $2.0M in an undisclosed round announced in Nov 2022.
1.4 years later, an undisclosed round of $1.2M was announced in Apr 2024.
2 months later, an undisclosed round of $4.0M was announced in Jun 2024.
4 months later, an undisclosed round of $4.0M was announced in Oct 2024.
Bio-Path Holdings Founders and Leadership Team
Contact details for the Bio-Path Holdings team: 1 of 2 have an email address on file.
Start 14-day free trial →Bio-Path Holdings Funding Compared to Other Biotechnology Startups
Bio-Path Holdings' latest round of $4.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Bio-Path Holdings in Biotechnology and Houston
Companies Similar to Bio-Path Holdings
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Bio-Path Holdings Funding FAQs
What does Bio-Path Holdings do?
Bio-Path is a biotechnology company developing DNAbilize, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous infusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and prexigebersen-A, a drug product modification of prexigebersen, is under consideration by the FDA to commence Phase 1 studies in solid tumors.
How much funding has Bio-Path Holdings raised?
Bio-Path Holdings has raised $11.2M across 4 rounds on record. The most recent is an undisclosed round of $4.0M announced in Oct 2024.
When did Bio-Path Holdings last raise funding?
Bio-Path Holdings' most recent funding round on record is an undisclosed round of $4.0M, announced in Oct 2024.
Who founded Bio-Path Holdings?
FundedIQ lists Ana Tari Ashizawa (Founder), Douglas P Morris (Founder) at Bio-Path Holdings.
Where is Bio-Path Holdings headquartered?
Bio-Path Holdings is based in Houston, Texas, United States.
How many employees does Bio-Path Holdings have?
Bio-Path Holdings is in the 1-10 employee band.
How does Bio-Path Holdings' funding compare to other Biotechnology startups?
Bio-Path Holdings' latest round of $4.0M is below the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Bio-Path Holdings Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Bio-Path Holdings is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.